TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $275

TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $220 to $275.